MichaelRaymondBurgessMDPhD
Oncology • San Francisco, CAHematologic Oncology
Executive Director, Translational Medicine at Celgene
Dr. Burgess is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
995 Potrero Ave
Bldg 80
San Francisco, CA 94110Phone+1 415-206-2407Fax+1 415-839-7018
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2013- University of California (San Francisco)Residency, Internal Medicine, 2007 - 2009
David Geffen School of Medicine at UCLAClass of 2007
University of California, Los AngelesPh.D., Molecular Biology, 2000 - 2005
Certifications & Licensure
CA State Medical License 2008 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Start of enrollment: 2015 Mar 12
- A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2016 Mar 01
- Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2018 Apr 03
- Join now to see all
Publications & Presentations
PubMed
- 123 citationsKRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.Michael R. Burgess, Eugene Hwang, Rana Mroue, Craig M. Bielski, Anica M. Wandler
Cell. 2017-02-23 - 79 citationsPreclinical efficacy of MEK inhibition in Nras-mutant AML.Michael R. Burgess, Eugene Hwang, Ari J. Firestone, Tannie Q. Huang, Jin Xu
Blood. 2014-12-18 - 73 citationsThe creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.Nina Fenouille, Christopher F. Bassil, Issam Ben-Sahra, Lina Benajiba, Gabriela Alexe
Nature Medicine. 2017-03-01
Press Mentions
Danette Mitchell: The Road to a Cure for Sickle Cell DiseaseDecember 9th, 2021- Amazon Launches Health Centers to Boost Employee Access to CareJuly 15th, 2020
Whistleblower Dr. Rick Bright Warns 'Window Is Closing' to Address Coronavirus in Congressional TestimonyMay 14th, 2020
Grant Support
- Postdoctoral FellowshipAmerican Cancer Society2014–2015
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
